Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Psoriasis Biosimilars Sector?
The market size for biosimilars for psoriasis has expanded at a swift pace in the past few years. The market is projected to increase from a worth of $7.32 billion in 2024 to $8.16 billion in 2025 with a compound annual growth rate (CAGR) of 11.5%. Various factors can be attributed to this growth during the historic period, including the escalating cost of original biologics, the efficacy and safety record of initial market entrants, widening of indications beyond just psoriasis, increase in chronic disease incidents, and modifications in hospital procurement policies.
In the forthcoming years, the psoriasis biosimilars market is anticipated to witness a swift expansion, reaching a worth of $12.43 billion in 2029, progressing at a compound annual growth rate (CAGR) of 11.1%. The growth projected for this period can be associated with factors such as a global rise in psoriasis cases, policy changes and interchangeability laws, growth in biosimilar production, enhanced education for patients and physicians, and the implementation of bundled pricing and value-based contracts. The forecast period is expected to be characterized by significant trends such as groundbreaking biosimilar manufacturing platforms, patient stratification driven by artificial intelligence, the introduction of sophisticated drug delivery devices, the development of next-generation formulations, and strategic collaborations in the industry.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27399&type=smp
What Forces Are Driving The Growth Of The Psoriasis Biosimilars Market?
Increased diagnosis rates of psoriatic arthritis are anticipated to boost the expansion of the psoriasis biosimilars industry in the future. Psoriatic arthritis is an autoimmune disease that triggers inflammation in joints and skin, usually affecting people with previous psoriasis instances. Detection and accurate diagnosis of psoriatic arthritis are becoming more common, mainly due to heightened screening procedures in individuals with psoriasis. These procedures are proficient in identifying minor joint symptoms that could have been overlooked in the past. Psoriasis biosimilars offer an economical alternative to biologic therapies for managing psoriatic arthritis, effectively mitigating joint inflammation and skin symptoms. As an illustration, in May 2024, the National Institutes of Health (NIH), an American government agency, reported that in 2022, the prevalence of psoriatic arthritis (PsA) was 0.221%, with an incidence rate of 13.54 per 100,000 people. Hence, the expanding rates of psoriatic arthritis diagnosis are propelling the psoriasis biosimilars market’s growth.
How Is The Psoriasis Biosimilars Industry Segmented Across Key Parameters?
The psoriasis biosimilars market covered in this report is segmented
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars
What Notable Trends Are Shaping The Direction Of The Psoriasis Biosimilars Market?
Key players in the psoriasis biosimilars market are prioritizing the development of unique solutions, including biosimilars for plaque psoriasis. These are aimed at increasing treatment availability, cutting healthcare expenses, and enhancing patient results. Biosimilars for such a condition are more affordable, yet comparable substitutes for validated biologic medicine utilized for this persistent autoimmune skin disorder marked by red, scaly patches. For example, Sandoz Group AG, a Swiss organization specializing in generic pharmaceuticals and biosimilars, rolled out the Pyzchiva autoinjector in May 2025. This is the first commercial ustekinumab biosimilar autoinjector. Pyzchiva is sanctioned for treating adult patients affected by plaque psoriasis, psoriatic arthritis, Crohn’s disease, and children aged six and above (weighing more than 60 kg) with plaque psoriasis. The autoinjector, designed to improve patient compliance and lifestyle, is notable for its precise automatic dosage, less painful injection, sleek structure, and adaptable storage options for an easier self-administration.
Which Companies Currently Dominate The Competitive Landscape In The Psoriasis Biosimilars Industry?
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report
Which Geographic Regions Are Driving Demand In The Psoriasis Biosimilars Market?
North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=27399&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model